Drug Eluting Pantera Lux Catheter Registry
Launched by BIOTRONIK AG · Mar 4, 2010
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
All patients are treated with the Pantera Lux Paclitaxel releasing balloon.
Clinical follow ups at 1, 6 and 12 months after coronary intervention.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Signed Patient Informed Consent / Data Release Form
- • Patient eligible for percutaneous coronary intervention (PCI)
- • Patient is older than 18 years of age
- • Exclusion Criteria
- • Patient has a known allergy against appropriate anticoagulation / antiplatelet therapy
- • Patients with known allergy against paclitaxel or BTHC
- • Patients with a target lesion that was previously treated by brachytherapy
- • Pregnant woman or lactating woman
About Biotronik Ag
Biotronik AG is a leading global medical technology company, headquartered in Berlin, Germany, specializing in innovative cardiovascular and endovascular solutions. With a strong commitment to advancing patient care, Biotronik develops cutting-edge devices and therapies that enhance the diagnosis and treatment of cardiovascular diseases. The company's extensive portfolio includes implantable cardiac devices, vascular interventions, and remote patient monitoring systems, all designed to improve clinical outcomes and quality of life. Biotronik AG is dedicated to rigorous clinical research and collaboration with healthcare professionals, ensuring the highest standards of safety and efficacy in its products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Segeberg, , Germany
Patients applied
Trial Officials
Raph Toelg, MD
Principal Investigator
Herz-Kreislauf-Zentrum, Segeberger Kliniken GmbH, Am Kurpark 1, 23795 Bad Segeberg, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials